Streetbeat News

Stock Prices

AWK

American Water Works (NYSE:AWK) has seen a 22.39% increase in short interest since its last report, with 2.82 million shares sold short, representing 1.64% of its float. This compares to a peer group average of 1.59%. The rise in short interest suggests a more bearish market sentiment towards AWK, but it's also noted that increasing short interest can sometimes be bullish.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

FN

Over the past 10 years, Fabrinet (NYSE:FN) has significantly outperformed the market, with an average annual return of 27.42%, turning a $1000 investment into $10,968.17. Currently, Fabrinet's market capitalization stands at $8.09 billion.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

HAL

Halliburton's (NYSE:HAL) short interest has decreased by 3.2%, now standing at 21.41 million shares or 2.72% of its float. This reduction suggests a more bullish market sentiment towards HAL compared to its last report. The company's short interest is also significantly lower than its peer group average of 7.74%, indicating a relatively positive outlook among investors. However, this does not guarantee a near-term price increase.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

FTNT

Over the past 10 years, Fortinet (NASDAQ:FTNT) has significantly outperformed the market with an annualized return of 21.1%, averaging 31.86% annually. An investment of $1000 in FTNT a decade ago would now be worth $15,534.17, showcasing the impact of compounded returns on investment growth. Fortinet's current market capitalization stands at $55.97 billion.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

CLAR

Clarus shares are trading higher following the announcement of their Q4 financial results and the issuance of FY24 net sales guidance.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:53 pm

FXI

SPY

President Biden has announced his intention to sign a bill concerning TikTok if it is passed by Congress. This statement indicates a significant step towards regulating or potentially taking action against the social media platform, which could have implications for US-China relations and the tech industry.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:51 pm

AMLX

ASLE

BBAI

JYNT

SGD

WLDN

U.S. stocks showed mixed performance with the Dow gaining over 100 points, while the Nasdaq and S&P 500 fell. AerSale shares plunged after reporting disappointing Q4 results. Nonfarm payrolls exceeded expectations, but the unemployment rate rose slightly. Willdan Group, The Joint Corp., and Safe and Green Development Corporation saw significant stock increases following positive financial news. Conversely, Amylyx Pharmaceuticals, AerSale Corporation, and BigBear.ai Holdings experienced substantial declines after reporting unfavorable outcomes.

Portfolio Pulse from Avi Kapoor

March 08, 2024 | 7:51 pm

AMPY

Trading of Amplify Energy's shares (AMPY) has been temporarily halted due to pending news, under a code news halt. This action typically indicates that significant news is about to be released that could materially affect the company's stock price.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 7:50 pm

JD

Financial analysts have observed a bullish trend in JD.com's (NASDAQ:JD) options trading, with 68% of trades being bullish. The analysis highlighted 16 unusual trades, with a significant number of calls over puts, indicating a positive sentiment towards JD.com. The price target for JD.com is set between $22.0 and $45.0, based on volume and open interest trends. JD.com's current market status shows a slight decrease in stock price with a potential overbought RSI indication. Market experts have issued a consensus target price of $38.8 for JD.com, with ratings ranging from Neutral to Buy.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:45 pm

NVO

PPH

The FDA has approved Novo Nordisk's Wegovy for expanded use in obesity and cardiovascular disease management, marking a significant advancement in preventive health strategies. This approval is based on the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events. Novo Nordisk's shares dipped 1.9% on the announcement day but have risen 90% over the past year. The VanEck Pharmaceuticals ETF, which holds a significant portion of Novo Nordisk shares, is also impacted.

Portfolio Pulse from Piero Cingari

March 08, 2024 | 7:36 pm